U.S. biomanufacturing is scaling fast. Faster, in fact, than most organizations are built to handle under regulatory scrutiny. U.S. biomanufacturing pledged investment since 2024, with pharmaceutical and life sciences companies pledging upwards of $26 billion in U.S. manufacturing capex in 2025 alone. New U.S. biomanufacturing facility announcements in 2024 and 2025 total nearly $50 billion.
Most organizations are treating these as parallel trends. In part, that is because investment and oversight are often managed by different stakeholders internally. Capital deployment, facility buildout and hiring are measured against growth targets, while inspection readiness sits within quality and regulatory functions. The result is a disconnect. For example, Eli Lilly has committed more than $50 billion to U.S. manufacturing expansion since 2020, while FDA inspection activity has also increased year over year. And the disconnect is reshaping where and how compliance and regulatory risk show up.
Staffing gaps are already compounding this pressure. Industry data shows more than one in three biopharma facilities report difficulty hiring process development staff, and more than one in four lack sufficient process engineers.
That shortage directly affects execution quality during expansion.
Expansion Is About Exposure, at Scale
There’s a common misconception in biopharma: inspections are discrete events. You prepare, you host, you respond.
But during expansion, inspection risk stops being a moment in time. It becomes a condition that builds over months. Inspection risk becomes a condition that snowballs over time, as findings accumulate, CAPAs begin stacking up, and unresolved observations carry forward into longer remediation cycles. If issues happen escalate beyond the initial inspection response, the burden can stretch for months. A federal watchdog review, for example, found follow-up inspections occurred nine months at least after warning letters were issued, on average.
From facility design through system implementation, tech transfer and validation execution, each decision either reduces or compounds the risk that will eventually surface under inspection.
That does not mean outcomes are fixed once an inspection begins. Pre-inspection audits, remediation efforts, documentation cleanup, leadership intervention and strong CAPA execution can materially improve results. But those efforts are often working within constraints created earlier. Structural gaps introduced during expansion are harder to unwind late in the process.
This isn’t because of what your team does that week, nor is it due to a last-minute mistake. It’s because of what was missed, rushed or misunderstood during expansion. It’s often a slow accumulation of small compromises made under pressure.
The New Risk Surface: Where Expansion Breaks Down
Expansion introduces complexity in ways that don’t always show up on a project plan.
A new facility isn’t just more capacity. It introduces:
- New expanded supply chain and distribution to deliver qualified materials and equipment to the new facility
- New systems that must meet evolving expectations around data integrity and validation
- New teams working across engineering, quality and operations, often without shared history
- New timelines that compress activities that were never meant to overlap
This is where risk begins to move upstream, and not usually in obvious ways. Subtle, compounding issues include:
CSV and Data Integrity Gaps
As systems become more complex, expectations around validation and data integrity are rising. Documentation that would have passed five years ago now invites deeper scrutiny.
FDA’s own inspection materials noted 57 FY2020 citations tied to 21 CFR 211.68(b), the computer-system control provision often associated with data integrity, and the agency continues to escalate these issues into formal enforcement. In September 2024 alone, FDA issued warning letters to two Chinese testing laboratories over data quality and integrity concerns. This all underscores just how aggressively documentation and system controls are now being scrutinized.
Tech Transfer Misalignment
What worked in development doesn’t always translate seamlessly to manufacturing – particularly with biologics and advanced therapies. Minute inconsistencies can create inspection vulnerabilities that surface too late.
Validation Under Time Pressure
Compressed timelines force overlap between commissioning, qualification and operational readiness. Assumptions get made, and assumptions rarely hold up under inspection.
Quality and Engineering Disconnects
Facilities get built. Systems and equipment get installed. But alignment the alignment is more often not tight enough between those building systems and those accountable for compliance. That gap is where regulatory findings exist.
These aren’t unusual issues. They’re predictable. That’s what makes them dangerous – and unsurprising.
The Default Response and Why It Falls Short
When risks start to rise, most organizations respond the same way: they add people. More QA resources, validation contractors and support to keep work moving.
In many cases, additional resources are necessary. Teams can be genuinely understaffed, particularly when documentation throughput, protocol execution, deviation investigation and closure or QA review bandwidth become bottlenecks.
But capacity alone does not resolve the underlying risk.
Regulatory risk comes from a lack of alignment, experience, and decision clarity in the moments that matter.
Adding more people under time pressure often introduces:
- More handoffs
- More inconsistency
- More oversight burden on already overstretched leaders
In regulated environments, increased activity without coordination can create more noise, not more control. Inspection risk is not purely a capacity problem. It is also a coordination and execution problem.
Frankly, that’s the difference between adding bodies and adding capability. Reliant Life Sciences provides experts who plug right into your team with the experience to navigate tight timelines, multiple stakeholders, and regulated execution without creating more burden. The result? Support that helps reduce pressure, improve coordination, and strengthen inspection readiness when it matters most.
The Burden That Leaders Are Actually Carrying
At the Director or VP level, whether in Quality, Manufacturing, or Regulatory, the conversation is not separate from headcount. It includes headcount, capability, timelines, and decision quality all at once.
Leaders are balancing questions like:
- Do we have enough coverage?
- Do we have the right expertise in critical roles?
- Are decisions being made consistently under pressure?
- Are the lines of communication and accountability clear to all involved?
When inspections go sideways, the impact is not abstract:
- Delayed approvals that push back product timelines and revenue projections
- Warning letters and Observations that often halt operations or trigger remediation programs
- Lost revenue tied directly to delayed commercialization
- Public reputational damage that can materially affect partnerships, valuation, and long-term viability
In some cases, companies have seen production delays stretch months or longer following regulatory findings, with dramatic financial impact.
Accountability is clear. Headcount, capability, judgment, and execution all sit with the same leadership team.
That’s the reality most staffing conversations fail to acknowledge.
Where Expansion Projects Actually Fail
For expansion projects that don’t result in success, it’s rarely the headline issues.
They fail in the grey areas:
- A validation package that looks complete but doesn’t align with current expectations
- A system that functions operationally but lacks defensible documentation
- A crucial deviation that was seemingly-resolved but not investigated deeply enough
- A data or documentation trail that exists but raises questions under scrutiny
Individually, these may not be catastrophic. Collectively, they tell a story.
Inspectors are not just evaluating systems. They are evaluating control.
When gaps form a pattern, confidence erodes quickly.
The Shift: From Staffing to First-Time-Right Execution
The organizations navigating this environment successfully are making a subtle shift.
The false dichotomy is that this is not about choosing between more people or better people. It is about aligning capacity with experience and execution quality.
Thin teams can make poor decisions under pressure. Overstaffed teams can introduce inconsistency without coordination.
The requirement is balance:
- Individuals who have operated in inspected environments, not just supported them
- Experts who understand what will hold up under current inspection standards and precedents
- Teams structured to make decisions efficiently without excessive escalation
In high-stakes expansions, delays are expensive. Rework under regulatory scrutiny is significantly more costly, often requiring revalidation, additional documentation cycles and extended timelines that delay revenue generation.
The cost of misalignment is not just inefficiency. It’s exposure.
Why This Moment Demands a Different Type of Partner
This is where the gap between traditional staffing models and current needs becomes clear.
Most firms are optimized for speed, volume, and coverage.
Those are valuable. But in regulated expansion, the challenge is not filling roles. It is ensuring execution holds up under inspection.
That requires:
- Context around regulatory expectations and enforcement trends
- Alignment across quality, engineering and operations
- Continuity from build through inspection
- Accountability for outcomes, not just placements
Without that, organizations can move quickly and still accumulate risk.
A Better Way to Think About Inspection Readiness
Inspection readiness during expansion is the byproduct of decisions made across long timelines, often 12 to 36 months depending on facility scope and complexity.
It spans:
- Facility design and build
- System & equipment integration and validation
- Tech transfer and process scale-up
- Documentation, governance, and Quality systems
Strong systems remain foundational. Talent does not replace weak validation plans, underscoped change management, or unclear accountability & ownership.
But people determine how those systems are interpreted, executed, and defended.
That includes:
- Recognizing risk early
- Challenging assumptions before they compound
- Understanding how inspectors evaluate decisions
- Operating in environments where concerns can be raised and addressed early
Execution quality creates inspection That confidence is built by people who have done this before, across multiple organizations and under real regulatory pressure. When you bring in experienced experts, you bring in the hard-won industry knowledge they carry within. This insight helps teams spot risk earlier, execute more cleanly, and hold up better under scrutiny if they’d acted without such support.
The Bottom Line
Biomanufacturing expansion isn’t slowing down. It’s doing the exact opposite. Regulatory scrutiny isn’t easing up – it’s transforming before our eyes. The intersection of these forces is where the highest-stakes challenges now live.
Organizations that treat this purely as a staffing problem will continue to run into the same issues. Those that align resource capacity, experience, and execution will move through inspections with fewer unexpected surprises and delays.
Experience improves the ability to identify weak points early, strengthen execution, and reduce downstream exposure to risk.
Simple Questions to Pressure-Test Your Inspection Readiness
Before your next meeting, ask:
- Where are we relying on assumptions instead of validated alignment?
- Which systems or processes would be difficult to defend today?
- Are our practices aligned with current expectations or legacy interpretations?
- Where are timelines forcing decisions that introduce risk?
- Do we have clear ownership, escalation paths, and decision authority during high-pressure phases such as validation and readiness?
- Has everyone on the team done this before – where it’s mattered most?
If those questions are difficult to answer, it’s worth addressing now while there’s still time to improve the outcome.
Ready to Reduce Inspection Risk During Expansion?
When timelines tighten and stakes rise, execution matters.
Reliant Life Sciences supports biopharma organizations with execution-ready talent across:
- CSV and data integrity
- CQV and validation
- Quality systems and regulatory strategy
- Facility expansion and tech transfer
Talk with a Reliant Life Sciences expert today to discuss your inspection readiness and expansion projects.